Two more for AtCor

By Kate McDonald
Monday, 08 December, 2008

Medical device company AtCor has signed two new supply agreements worth US$1.5 million for its reflected blood pressure measurement system SphygmoCor.

The new agreements cap an excellent six months for the Sydney company, with supply contracts signed in the period worth US$5.7 million.

The device is aimed at both clinical practice and clinical trials to understand drug efficacy and mechanisms of action.

The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd